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1. Introduction 
At the beginning of twenty century Alois Alzheimer described the pathology that now bears 
his name (Alzheimer, 1907). Over a hundred years later, Alzheimer’s disease (AD) is the 
most common cause of dementia in developed countries. Here eighteen million people are 
currently affected and the number of patients is expected to increase dramatically with the 
ongoing increase in the elderly population (Fotuhi et al., 2009, Mount & Downton, 2006). 
Because no suitable biomarkers are available, the diagnosis of AD remains inconclusive 
until postmortem pathological analysis, and physicians rely on behavioral manifestations to 
differentiate between AD and other conditions. For this reason firm diagnosis is generally 
only made at later stages of the disorder when treatment is purely palliative. These features 
make AD a social and economic challenge in developed countries (Wimo et al., 2010). 
Clinically, AD is characterized by progressive loss of cognitive functions with specific 
deficits in episodic memory. Clinical diagnosis of is generally only made when cognitive 
deficits are sufficiently severe to cause dependent status of the patient (Nestor et al., 2004). 
Pathological analyses of AD brain have described two distinct types of proteinopathy in the 
frontal and temporal lobes involving the limbic system and the basal forebrain. The first 
type comprises aggregates of beta-amyloid peptide (Aβ) – a specific fragment of the amyloid 
precursor protein (APP), a plasma membrane protein. These aggregates accumulate in the 
extracellular space and give rise to senile plaques (SPs). SPs cause synaptotoxicity, 
neurotoxicity, oxidative stress and hypoxia (Peers et al., 2009, Selkoe, 2001, 2008). The 
second proteinopathy occurs in the cytosol. Hyperphosphorylation and abnormal 
aggregation of the microtubule-associated protein tau leads to the intracellular formation of 
neurofibrillary tangles (NFTs) which cause cytoskeleton destabilization and eventually cell 
death (Hernandez & Avila, 2008, Selkoe, 2001).  
It has been widely reported that olfactory loss (anosmia and hyposmia) takes place in the 
early stages of AD, and before any detectable cognitive deficits are present. Interestingly, 
AD pathology extends throughout the limbic system and the basal forebrain, including the 
olfactory system (Braak & Braak, 1991). The human olfactory system includes peripheral 
sensory neurons in the olfactory epithelium; these send their axons across the cribriform 
plate of the etmoides bone to the olfactory bulbs. In the glomerular layer of the olfactory 
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bulbs their axons synapse with dendrites of the mitral and tufted cells which in turn project 
to the main olfactory cortex in the basal forebrain. The human olfactory system constitutes 
complex circuit connections including primary and secondary cortical areas that are 
connected, as represented schematically in Figure 1. 
 
 
Fig. 1. Schematic diagram of the human olfactory system. GL, glomerular layer; Mi, mitral 
cell; PAC, periamygdaloid complex; Pg, periglomerular cell. 
The progression of AD pathology has been divided into six stages according to the extent of 
NFT accumulation. Accumulation is first detected in the entorhinal cortex and hippocampus 
of the limbic system; this extends into the basal forebrain including the olfactory system 
(Braak & Braak, 1991, Price et al., 1991, Van Hoesen et al., 1991), and from the rostral 
entorhinal cortex, periamygdaloid cortex, and piriform cortex, to the olfactory tubercle, 
anterior olfactory nucleus and olfactory bulbs (Fig. 1). Tau pathology has also been 
described in the olfactory epithelium (Lee et al., 1993). Olfaction is affected in many 
psychiatric disorders in addition to AD, including Parkinson’s disease, Huntington’s 
disease, schizophrenia, senile dementia of Lewy body type, and depression (Atanasova et 
al., 2008,Kovacs, 2004). It has been widely reported over the past 25 years that olfaction is 
impaired in AD (Djordjevic et al., 2008, Doty et al., 1987, Mesholam et al., 1998, Murphy, 
1999, Murphy et al., 1990, Serby et al., 1985, 1991), and olfaction has become a priority area 
in the search for biomarkers to establish an early diagnosis of AD and to facilitate early 
therapeutic intervention (Doty, 2003,Hampel et al., 2010,Hawkes, 2009,Wilson et al., 2009). It 
has been proposed that the early involvement of the entorhinal cortex and the hippocampus, 
regions that are tightly related to memory deficiencies (Nagy et al., 1996), could be also the 
cause of olfactory deficits (Wilson et al., 2007). However, other authors suggest that 
alternative olfactory areas, for example the posterior part of the piriform cortex, are the 
specific cause of olfactory deficiencies (Li et al., 2010). Nevertheless, the neural basis 
underlying hyposmia in the AD brain remain uncertain.  
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2. Materials and methods 
We have studied the olfactory system in 19 AD cases and 7 age-matched controls from the 
Banc de Teixits Neurològics, Universitat de Barcelona-Hospital Clínic and the Banco de 
Tejidos/Fundación para Investigaciones Neurológicas, Universidad Complutense de 
Madrid. Mean ages (± standard derivation) in AD and controls were 77.68 ± 9.01 yr and 
74.57 ± 4.47 yr, respectively. Tissue samples were fixed by immersion in paraformaldehyde 
4% for one month at least. Then, samples were cryoprotected in 30% w/v sucrose and 50µm 
coronal sections were obtained using a sliding freezing microtome. 
To study the early stages of disease development we employed a double transgenic mouse 
model of Alzheimer disease (Appswe/Psen1Δ9). Animals at 2, 4, 6 to 8 months of age (n = 4 
homozygous and 4 control female mice per group; N = 32) were collected for analysis. 
Animals were anesthetized with a mixture of ketamine hydrochloride (Ketolar, Parke-Davis, 
Madrid, Spain, 1.5 ml/kg, 75 mg/kg) and xylazine (Xilagesic, Calier, Barcelona, Spain, 0.5 
ml/kg, 10 mg/kg). Mice were transcardially perfused with saline solution followed by 4% 
w/v paraformaldehyde fixative (phosphate buffered; 0.1 M, ph 7.2). Brains were removed 
from skulls and cryoprotected in 30% w/v sucrose, and sectioned (50 µm) in the frontal 
plane (brains) or in the sagittal plane (olfactory bulbs) using a sliding freezing microtome.  
In order to delimit areas of interest sections were stained by Nissl technique (Fig. 2A). 
Primary antibodies used for immunodetection were mouse anti-tau (tau 46, 1:800, Cell 
Signaling Technology, Beverly, MA, USA), rabbit anti-Aǃ (1:250, Cell Signaling Technology), 
and goat anti-somatostatin D-20 (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
Secondary antibodies were either biotinylated (anti-goat IgG, 1:2000, Vector Laboratories, 
Burlingame, CA, USA) or fluorescent-labeled (1:200, alexas 488 donkey anti-mouse, 568 
donkey anti-rabbit, and 350 donkey anti-goat; Molecular Probes, Invitrogen, Carlsbad, CA, 
USA).  
For quantification, somatostatin-positive cells were charted with an X-Y recording system 
(AccuStage, Minnesota Datametrics, MN, USA). Colocalization levels were measured by 
confocal microscopy using LSM 710 Zeiss confocal microscope (Carl Zeiss MicroImaging, 
Barcelona, Spain). Intensities of each fluorochrome were analyzed using the profile tool of 
the ZEN software (Zeiss).  
One-way ANOVA followed by post hoc Bonferroni test (p<0.05) was used to estimate 
significant differences among markers and age groups.  
3. Interneurons in the olfactory system 
Interneurons constitute 20–30% of the neuronal population of the cerebral cortex and 
possess distinct morphological, electrophysiological and neurochemical characteristics 
(Ascoli et al., 2008,DeFelipe, 1997,Markram et al., 2004). Two primary features are common 
to all interneuron subpopulations. First, these cells are predominantly inhibitory 
interneurons which express Ǆ-aminobutyric acid (GABA), an inhibitory neurotransmitter; 
and, second, their neuronal connectivity is predominantly restricted to the local region of 
the brain (DeFelipe & Farinas, 1992, Kawaguchi & Kondo, 2002). 
Interneurons are tightly related to the pathoetiology of AD, and many reports have 
described the involvement of interneuron subpopulations in AD neuropathology (Attems et 
al., 2008, Brady & Mufson, 1997, Geula et al., 2003, Saiz-Sanchez et al., 2010, Solodkin et al., 
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1996, Supnet & Bezprozvanny). It was recently reported that numbers of interneurons in the 
entorhinal cortex and hippocampus are significantly reduced in early AD stages (Koliatsos 
et al., 2006). Interneurons regulate synaptic signaling by pyramidal neurons and the loss of 
this regulation could produce deficits in learning and memory (Palop et al., 2003, 
Wallenstein & Hasselmo, 1997). Moreover, disregulation of olfactory information-processing 
due to loss of interneurons could underlie the hyposmia described in the early stages of the 
disease. This review focuses on four major types of interneurons based on their importance 
to AD etiology and brain calcium homeostasis: respectively cells expressing somatostatin, 
calbindin, calretinin or parvalbumin. We also discuss the distribution of different types of 
interneurons and their involvement with tau and β-amyloid pathology as revealed by 
confocal microscopy. 
3.1 Somatostatin 
The neuropeptide somatostatin is implicated in diverse functions in the central nervous 
system (Epelbaum, 1986, Viollet et al., 2008). Somatostatin is expressed in all olfactory areas. 
Recently, somatostatin has been linked with AD etiology because it is reported to act as a 
positive regulator of neprilysin, an enzyme which catalyzes the degradation of β-amyloid 
peptide (Saito et al., 2005). Somatostatin levels decline with aging (Lu et al., 2004) and are 
further reduced in AD (Davies et al., 1980). It has been proposed that the decline in 
somatostatin levels with age could explain the age-dependency of AD onset because 
reduced somatostatin would be expected to lead to downregulation of neprilysin activity, 
thereby predisposing to the accumulation of β-amyloid peptide (Hama & Saido, 2005). 
Confocal microscopy of the olfactory system in AD brain has revealed that somatostatin is 
selectively reduced, by up to 50%, in olfactory areas such as anterior olfactory nucleus 
(AON). Moreover, the deficiency in somatostatin was predominantly associated with ǃ-
amyloid pathology rather than tau pathology (Figs 2, 3). These findings are in agreement 
with the theory of Hama & Saido that there is a tight relationship between somatostatin and 
β-amyloid. The AON is an important relay in olfactory information processing (Price, 1990). 
Two distinct portions of the AON can be distinguished in the basal forebrain – the medial 
AON and the lateral AON divided by the olfactory tract (Fig. 2A). The AON is an early site 
for the accumulation of tau protein (Fig. 2B) (Price et al., 1991) and is also targeted for β-
amyloid deposition (Fig. 2C). Somatostatin-expressing cells in the AON possess typical 
bipolar interneuron morphology. Confocal analyses show that most somatostatin-cells 
expressing are not associated with tau pathology (Figs 2E, F and 3), and somatostatin-
expressing cells are most commonly associated with β-amyloid or with β-amyloid plus tau 
(Figs 2F and 3). 
In Appswe/Psen1Δ9 mice, somatostatin is expressed in all olfactory areas. Expression levels 
decline with age, and are most markedly reduced in the areas where AD initiates, for 
example the entorhinal cortex. As in the human AD brain, confocal analyses of the olfactory 
system of double transgenic mice revealed a correlation between somatostatin expression 
and β-amyloid pathology. Colocalization with β-amyloid peptide was very extensive and 
was evident in the youngest animals analyzed. Colocalization was seen in all olfactory areas 
with the exception of the olfactory bulb. Notably, colocalization of somatostatin-expressing 
interneurons with β-amyloid peptide was evident (Figs 4, 5), even in the absence of reduced 
levels of somatostatin expression.  
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Fig. 2. Expression of somatostatin, tau and ǃ-amyloid in the anterior olfactory nucleus 
(AON) in Alzheimer’s disease. (A) Nissl staining of AON in the basal forebrain. (B) 
Immunohistochemistry of tau protein (blue arrow, dystrophic neuron; blue arrowhead, 
cellular debris). (C) ǃ-Amyloid positive senile plaques in AON. (D) Somatostatin-expressing 
cell in the AON showing a dystrophic neuron (black arrow). (E) Double 
immunofluorescence for somatostatin (green) and tau protein (red). Confocal image of triple 
immunofluorescence for somatostatin (blue), ǃ-amyloid (red) and tau (green). Note a 
neuron positive only for tau protein (white arrowhead) and a typical senile plaque (red). 
Scale bar: A = 400 µm, B & F = 80 µm, D, C & E = 40 µm. 
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Fig. 3. Percentage of the three different types of colocalization of somatostatin-expressing 
cells (SOM) with tau protein (tau) and β-amyloid peptide (Aβ) in the human anterior 
olfactory nucleus. 
 
 
Fig. 4. Percentages of somatostatin and ǃ-amyloid colocalization in the APPswe/PSEN1Δ9 
mice olfactory system. Note that the external plexiform layer from the olfactory bulb is 
absent. AON, anterior olfactory nucleus; LEnt, lateral entorhinal cortex; Pir, piriform cortex; 
Tu, olfactory tubercle. 
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All olfactory areas showed a marked accumulation of β-amyloid deposits, but the extent of 
accumulation in olfactory tubercle (Tu) was less than in other areas (Fig. 5A–D). The greatest 
reduction in cells expressing somatostatin was seen in the external plexiform layer (EPL) 
(Fig. 5E,F) of the olfactory bulb, the piriform cortex (Pir) and the entorhinal cortex (Ent). In 
addition, the olfactory tubercle (Tu) and anterior olfactory nucleus (AON) both showed  
significant reductions in levels of somatostatin-positive cells. Different forms of 
colocalization were observed, including isolated cells (Fig. 5G), fibers and cell debris (Fig. 
5H, I). Colocalization increased with age and was greater in caudal olfactory areas than in 
rostral areas. No colocalization was found in the external plexiform layer of the olfactory 
bulb where β-amyloid pathology was restricted to the granule cell layer (Fig. 5A,D) and was 
largely absent from the EPL. 
 
 
Fig. 5. Somatostatin and ǃ-amyloid in the olfactory system of APPswe/PSEN1Δ9 mice. 
Green, ǃ-amyloid;  red, somatostatin. Immunohistochemistry for ǃ-amyloid in the olfactory 
bulb (A), including anterior olfactory nucleus, piriform cortex and olfactory tubercle (B) and 
entorhinal cortex (C). Immunofluorescence in the olfactory bulb for ǃ-amyloid (D) and 
somatostatin in a control mouse (E) and 6 months old transgenic mice (F). Confocal images 
demonstrating ǃ-amyloid colocalization with somatostatin-expressing cells (G), fibers and 
cell debris (H, I). Scale bar:  A, B, C & D = 400 µm, E & F = 80 µm, G & H = 40 µm, I = 25 µm 
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3.2 Calcium-binding proteins 
Calcium is an intracellular second messenger that mediates physiological responses of 
neurons to chemical and electrical stimulation. In AD defective calcium homeostasis is 
thought to cause aberrant cellular metabolism and promote cell death (Heizmann & Braun, 
1992, Mattson, 2007). Calcium has been related to changes in learning (Foster, 2007, Palop et 
al., 2003) and altered calcium regulation has been reported in AD brains before any 
cognitive deficits become apparent (Bezprozvanny & Mattson, 2008).   
Our analysis focused on three interneuron subpopulations expressing three different 
calcium-binding proteins (CaBP): calbindin, calretinin and parvalbumin. All three proteins 
are expressed in the olfactory system, but with different distributions. 
3.3 Calbindin 
Most studies on calbindin D-28k have concluded that there is a general decline in levels in 
AD brain compared to controls (Ferrer et al., 1993, Iacopino & Christakos, 1990, Ichimiya et 
al., 1988).  
In AD brain, calbindin D-28k is expressed widely throughout the olfactory system and is 
particularly abundant in key structures of olfactory processing such as the AON (Fig. 6A,B) 
and the piriform cortex (Fig. 6C). Especially evident is the pathological involvement of 
calbindin 28-Dk in the piriform cortex (Fig. 6C) where aberrant morphologies of calbindin-
expressing dystrophic neuritis can be observed (Fig. 6D). Although calbindin-positive cells 
in the human olfactory system show some involvement with β-amyloid pathology, there 
was a stronger association with tau pathology (Fig. 6E, F). 
 
 
Fig. 6. Calbindin D-28k in the olfactory system of Alzheimer’s disease brain. Green, tau 
protein and red, calbindin D-28k. (A) Nissl staining of the human anterior olfactory nucleus 
(AON). (B) Calbindin- expressing cell in the AON. (C) Calbindin- expressing cell in the 
piriform cortex (Pir). (D) Detail of a dystrophic neurite. (E) Tau pathology in Pir. (F) 
Calbindin-expressing cell with associated tau pathology. Scale bar: A = 160 µm, B & C = 80 
µm, E = 40 µm, D & F = 25 µm. 
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3.4 Calretinin 
Whereas calbindin D-28k is firmly associated with AD neuropathology, the involvement of 
calretinin in AD is more controversial (Brion & Resibois, 1994, Fonseca & Soriano, 1995, Hof 
et al., 1993, Sampson et al., 1997). Some authors propose that calretinin-positive cells are 
resistant to disease progression as a result of its capacity to buffer intracellular calcium 
levels. Furthermore, the potential role of calretinin in the neural basis of hyposmia remains 
unclear. We have studied the distribution of calretinin distribution in the human olfactory 
system and its involvement by tau and β-amyloid pathology. 
Microscopy observations revealed that calretinin is present throughout the olfactory system. 
AD brain expression levels were found to be markedly reduced in olfactory areas such as 
AON (Fig. 7B) and Pir (Fig. 7C) relative to control brain (Fig. 7D). As with calbindin-
expressing cells, calretinin-positive cells showed aberrant morphologies. In addition, these 
cells showed preferential involvement of tau pathology. In the olfactory bulb calretinin was 
found to be expressed in the periglomerular cells (Fig. 7A). It is interesting to note that 
sensory neurons from the olfactory epithelium send their axons to glomeruli in the olfactory 
bulb where they make synapses with dendrites of mitral cells. These synapses are regulated 
by periglomerular cells (Fig. 1). Involvement of periglomerular cells could therefore lead to 
disregulation of olfactory perception at the early stages of the disease. 
 
 
Fig. 7. Calretinin-expressing cells in the human olfactory system. (A) Periglomerular cells in 
the glomerular layer (GL) in the human olfactory bulb. (B) Calretinin-expressing cells in the 
anterior olfactory nucleus (AON). Expression of calretinin in (C) control and (D) 
Alzheimer’s disease piriform cortex (Pir). Scale bar: A & B = 80 µm, C & D = 400 µm.  
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3.5 Parvalbumin 
The third subclass of interneurons studied were those expressing parvalbumin. As with 
calretinin, the involvement of parvalbumin in AD is controversial. On the one hand it has 
been reported that there is an up to 60% decrease in the parvalbumin-positive cell 
population in AD hippocampus (Brady & Mufson, 1997) and entorhinal cortex (Mikkonen et 
al., 1999, Solodkin et al., 1996). On the other, no association was found between 
parvalbumin-positive cells and tau pathology in AD  (Sampson et al., 1997).  
In the human brain parvalbumin-expressing cells were present throughout the olfactory 
system and were particularly abundant in caudal olfactory areas such as piriform cortex 
(Fig. 8) and entorhinal cortex. In contrast to cells expressing calbindin- and calretinin, 
parvalbumin-positive cells showed physiological morphology, even at advanced stages of 
disease (Fig. 8A, B). Confocal images showed that parvalbumin-positive cells were 
predominantly associated with tau pathology (Fig. 8C); there was less evidence of 
involvement with β-amyloid pathology. As with calbindin- and calretinin-expressing cells, 
tau/NFT was the predominantly neuropathology associated with these calcium-binding 
proteins. 
 
 
Fig. 8. Parvalbumin-expressing cells in the human olfactory system. Green, tau protein and 
red, parvalbumin. Immunohistochemistry of Alzheimer (A) and control (B) brain piriform 
cortex (Pir). (C) Confocal image of the Pir demonstrating the association of parvalbumin-
expressing cells with tau pathology. Scale bar: A & B = 80 µm, C = 25 µm. 
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4. Discussion 
In the present report we have studied the involvement of interneuron populations in the 
human olfactory system with AD neuropathology as revealed by two different disease 
markers: tau protein and β-amyloid peptide. Somatostatin-expressing interneurons in the 
olfactory system were preferentially associated with β-amyloid pathology in both AD brain 
and in Appswe/Psen1Δ9 mice. By contrast, interneurons expressing different calcium-binding 
proteins were predominantly associated with tau pathology. In transgenic mice, cells 
expressing  Somatostatin-cell expressing was colocalized with ǃ-amyloid pathology in the 
youngest animals examined, with the exception of the external plexiform layer, and the 
colocalization was evident even before disease-related reduction in the numbers of 
somatostatin cells. 
The four subpopulations of interneurons were not randomly distributed within the olfactory 
system. Somatostatin-expressing cells were present in the olfactory bulb but were restricted 
to the external plexiform layer (EPL) (Fig. 5). Somatostatin was also present in other 
olfactory areas, particularly in the anterior olfactory nucleus (AON). Calbindin-expressing 
cells were present in the olfactory system, and were particularly abundant in the AON. 
Calretinin-positivity constitutes a specific marker for periglomerular cells which regulate the 
first relay of olfactory information from the olfactory epithelium to the olfactory bulbs (Fig. 
1). Calretinin-expressing cells were also abundant in the piriform cortex (Pir) and the 
entorhinal cortex (Ent). Parvalbumin-positive cells were more abundant in the more caudal 
areas studied (Pir and Ent) and were only sparsely distributed in rostral olfactory areas. 
The wide presence of these interneuron populations in olfactory structures and the severe 
and early involvement of these regions in AD neuropathology has focused attention on the 
role of these cells in the pathoetiology of AD. Generalized involvement of these cells and 
loss of interneuron populations and/or disregulation of their primary projection cells could 
underlie the olfactory deficits of AD patients. Loss of inhibitory regulation by -
aminobutyric acid (GABA) could lead to altered firing patterns of projection neurons. 
The olfactory system encompasses complex interconnections between several cortical areas 
(Fig. 1). Although it remains unknown whether dysfunction of specific interneuron 
populations in any given area could cause the olfaction deficits seen in AD, we report that 
there was selective association between different types of interneuron and AD 
neuropathology, as revealed by the two pathological markers employed in this study. 
However, it is not yet possible to relate these changes with specific olfaction deficits such as 
preferential or general anosmia, hyposmia or dysosmia. The specific contribution of each 
area in olfactory processing and how they are differentially affected during AD will need to 
be resolved before a specific olfactory test can be devised that could permit early diagnosis 
of AD.  
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